InvestorsHub Logo
Post# of 249959
Next 10
Followers 788
Posts 118622
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 237783

Thursday, 06/03/2021 6:45:45 PM

Thursday, June 03, 2021 6:45:45 PM

Post# of 249959
BMY releases additional Opdivo/chemo and Opdivo/Yervoy data from the CHECKMATE-648 study in certain GI cancers:

In Apr 2021, BMY announced that this study hit its OS primary endpoint for both the Opdivo/chemo and Opdivo/Yervoy arms, compared to chemo alone (#msg-163050617), but no details were available until now.

The dataset is complex and you need a scorecard to understand all of it; fortunately, Evaluate Vantage has provided one:

Note: Opdivo/chemo is already FDA-approved in a different kind of metastatic GI cancer, based on the CHECKMATE-649 (rather than -648) study (#msg-163247972); and Opdivo monotherapy is already FDA-approved in adjuvant esophageal cancer, based on the CHECKMATE-577 study (#msg-163936079).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.